Citius Oncology provides commercial update on lymphir launch

Citius Oncology (CTOR)provided a commercial update on the U.S. launch of lymphir for the treatment of cutaneous T-cell lymphoma, highlighting continued adoption across leading oncology centers, broad payer coverage progress, and advancing investigator-led clinical studies. Launch highlights include: sequential growth in orders from target institutions since launch, with initial accounts already placing repeat orders; institutional uptake of 83% of target accounts having added or actively progressing lymphir through formulary review; expanding market access with ~135 health plans, representing ~80% of covered lives; no reported reimbursement denials or prior authorization barriers; initial penetration into community infusion centers underway with patients beginning to transition from larger cancer centers; and commercial buildout proceeding, with field team onboarding in the coming month and broader field expansion in progress. International expansion is underway through executed distribution agreements across Europe and the Middle East. In parallel, Citius Oncology is advancing lymphir’s clinical development through collaborations with leading academic centers to further evaluate its potential across broader oncology settings.